Show simple item record

dc.contributor.authorGarcia-Robledo, Juan Esteban
dc.contributor.authorRosell, Rafael
dc.contributor.authorRuíz-Patiño, Alejandro
dc.contributor.authorSotelo, Carolina
dc.contributor.authorArrieta, Oscar
dc.contributor.authorZatarain-Barrón, Lucia
dc.contributor.authorOrdoñez, Camila
dc.contributor.authorJaller, Elvira
dc.contributor.authorRojas, Leonardo
dc.contributor.authorRusso, Alessandro
dc.contributor.authorde Miguel-Pérez, Diego
dc.contributor.authorRolfo, Christian
dc.contributor.authorCardona, Andrés F
dc.date.accessioned2022-02-10T14:15:35Z
dc.date.available2022-02-10T14:15:35Z
dc.date.issued2022-01
dc.identifier.urihttp://hdl.handle.net/10713/17931
dc.description.abstractNon-small-cell lung cancer (NSCLC) is a heterogeneous disease, and therapeutic management has advanced to identify various critical oncogenic mutations that promote lung cancer tumorigenesis. Subsequent studies have developed targeted therapies against these oncogenes in the hope of personalized treatment based on the tumor's molecular genomics. This review presents a comprehensive review of the biology, new therapeutic interventions, and resistance patterns of two well-defined subgroups, tumors with KRAS and MET alterations. We also discuss the status of molecular testing practices for these two key oncogenic drivers, considering the progressive introduction of next-generation sequencing (NGS) and RNA sequencing in regular clinical practice.en_US
dc.description.urihttps://doi.org/10.1177/17534666211066064en_US
dc.language.isoenen_US
dc.publisherSAGE Publications Inc.en_US
dc.relation.ispartofTherapeutic Advances in Respiratory Diseaseen_US
dc.subjectKRASen_US
dc.subjectMETen_US
dc.subjectbiomarkeren_US
dc.subjectdirected therapyen_US
dc.subjectgenomic profilingen_US
dc.subjectnon-small-cell lung canceren_US
dc.subjectresistanceen_US
dc.subjecttargeted therapyen_US
dc.subjecttumor genomicsen_US
dc.titleKRAS and MET in non-small-cell lung cancer: two of the new kids on the 'drivers' block.en_US
dc.typeArticleen_US
dc.identifier.doi10.1177/17534666211066064
dc.identifier.pmid35098800
dc.source.journaltitleTherapeutic advances in respiratory disease
dc.source.volume16
dc.source.beginpage17534666211066064
dc.source.endpage
dc.source.countryEngland


This item appears in the following Collection(s)

Show simple item record